Compare PRG & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | FTRE |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2020 | 2023 |
| Metric | PRG | FTRE |
|---|---|---|
| Price | $38.52 | $16.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $50.00 | $14.06 |
| AVG Volume (30 Days) | 365.0K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | $2,409,223,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $23.77 | N/A |
| Revenue Next Year | $7.91 | $3.09 |
| P/E Ratio | $41.72 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $25.80 | $4.46 |
| 52 Week High | $41.14 | $18.67 |
| Indicator | PRG | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 63.11 |
| Support Level | $32.30 | $15.66 |
| Resistance Level | $38.57 | $18.08 |
| Average True Range (ATR) | 1.48 | 1.09 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 77.00 | 78.80 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.